Trial Profile
ImmunTraCkeR testing before and during treatment with ipilimumab in patients with metastatic melanoma
Status:
Recruiting
Phase of Trial:
Clinical Phase Unknown
Latest Information Update: 06 Aug 2015
Price :
$35
*
At a glance
- Drugs Ipilimumab (Primary)
- Indications Malignant melanoma
- Focus Biomarker; Pharmacodynamics
- Acronyms PREDICT-ID
- Sponsors ImmunID
- 16 Dec 2014 New trial record
- 10 Dec 2014 This study has been authorised by French regulatory bodies and is expected to start in January 2015, according to an ImmunID media release.